[go: up one dir, main page]

AR105047A1 - Métodos para el tratamiento de mujeres por el trastorno de deseo sexual hipoactivo (hsdd) con un tratamiento de combinación de bupropion y trazodona - Google Patents

Métodos para el tratamiento de mujeres por el trastorno de deseo sexual hipoactivo (hsdd) con un tratamiento de combinación de bupropion y trazodona

Info

Publication number
AR105047A1
AR105047A1 ARP160101828A ARP160101828A AR105047A1 AR 105047 A1 AR105047 A1 AR 105047A1 AR P160101828 A ARP160101828 A AR P160101828A AR P160101828 A ARP160101828 A AR P160101828A AR 105047 A1 AR105047 A1 AR 105047A1
Authority
AR
Argentina
Prior art keywords
treatment
hsdd
bupropion
women
methods
Prior art date
Application number
ARP160101828A
Other languages
English (en)
Inventor
G Sitchon Nick
Meston Cindy
Katz Molly
Drogatis Leonard
Taylor Segraves Robert
Clayton Anita
E Pyke Robert
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of AR105047A1 publication Critical patent/AR105047A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para el tratamiento de mujeres por el trastorno de deseo sexual hipoactivo (HSDD) con tratamientos diarios orales de combinaciones de dosis baja y dosis alta de trazodona y bupropion.
ARP160101828A 2016-06-17 2016-06-21 Métodos para el tratamiento de mujeres por el trastorno de deseo sexual hipoactivo (hsdd) con un tratamiento de combinación de bupropion y trazodona AR105047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
AR105047A1 true AR105047A1 (es) 2017-08-30

Family

ID=57758862

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160101828A AR105047A1 (es) 2016-06-17 2016-06-21 Métodos para el tratamiento de mujeres por el trastorno de deseo sexual hipoactivo (hsdd) con un tratamiento de combinación de bupropion y trazodona
ARP160101856A AR105087A1 (es) 2016-06-17 2016-06-21 Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP160101856A AR105087A1 (es) 2016-06-17 2016-06-21 Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona

Country Status (9)

Country Link
KR (1) KR20170142797A (es)
AR (2) AR105047A1 (es)
AU (1) AU2016204151A1 (es)
CA (1) CA2933921A1 (es)
CL (1) CL2016001597A1 (es)
MX (1) MX2016008272A (es)
PE (1) PE20180023A1 (es)
UY (1) UY36742A (es)
WO (1) WO2017218018A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
US9517254B2 (en) * 2012-08-06 2016-12-13 S1 Biopharma, Inc. Treatment regimens

Also Published As

Publication number Publication date
UY36742A (es) 2016-12-30
PE20180023A1 (es) 2018-01-09
WO2017218018A1 (en) 2017-12-21
CA2933921A1 (en) 2017-12-17
MX2016008272A (es) 2017-12-18
KR20170142797A (ko) 2017-12-28
CL2016001597A1 (es) 2017-10-06
AU2016204151A1 (en) 2018-01-18
AR105087A1 (es) 2017-09-06

Similar Documents

Publication Publication Date Title
CL2019001685A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
TWD187898S (zh) 按摩器
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
NI201500062A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
MX2015011753A (es) Metodos para tratar cancer de vegija.
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX2017004629A (es) Compuesto heterociclico.
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
MX2017004569A (es) Inhibidores de gingipaina de lisina.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MX2017009863A (es) Agente preventivo y/o terapeutico de enfermedad inmune.
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure